In pooled analysis of four trials, the RR (95% CIs) for the composite outcome of cardiovascular death or HF hospitalization was 0.88 (0.76–1.02; I2 = 51%; 95% CI 0, 84%; p for heterogeneity = .11) when comparing SGLT2‐Is with placebo in those on RAAS‐I treatment at baseline. The gene discussed is SLC5A2; the disease is hydrops fetalis.